New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR), Krispy Kreme Doughnuts (NYSE:KKD), ChemoCentryx Inc (NASDAQ:CCXI), Mitsui & Co Ltd (ADR) (OTCMKTS:MITSY)
Petroleo Brasileiro Petrobras SA (ADR) (NYSE:PBR) the stock opened the session at $14.00but then moved to $14.02. At that price, the stock showed a negative performance of -0.78%. Petroleo Brasileiro SA Petrobras (Petrobras) is a Brazil-based integrated oil and gas company. The Company divides its activities into seven segments: Exploration and Production; Refining, Transportation and Marketing; Gas and Power; Biofuel; Distribution and International. Directly or through its subsidiaries, Petrobras is engaged in the research, extraction, refining, processing, trade and transport of oil from wells, shale and other rocks, its derivatives, natural gas and other liquid hydrocarbons,
Will PBR Get Buyers Even After The Recent Rally? Find Out Here
Krispy Kreme Doughnuts (NYSE:KKD) opened the session at $19.59and closed the session at $20.21. The stock showed a positive performance of 3.16% in previous trading session. Krispy Kreme Doughnuts, Inc. (Krispy Kreme) is a retailer and wholesaler of doughnuts complementary beverages and treats and packaged sweets. The Company’s principal business is owning and franchising Krispy Kreme stores, at which a variety of doughnuts, including the Company’s Original Glazed doughnut, are sold and distributed together with complementary products,
For How Long KKD will fight for Profitability? Read This Trend Analysis report
ChemoCentryx Inc (NASDAQ:CCXI) opened the session at $5.22 and closed the session at $5.16. The stock showed a positive performance of 2.79% in previous trading session. ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors,
Why Should Investors Buy CCXI After The Recent Gain? Just Go Here and Find Out
Mitsui & Co Ltd (ADR) (OTCMKTS:MITSY) the stock decreased -0.19% and finished the session at $268.75. Traded with volume of 13,066.00 shares in the prior session and the average volume of the stock remained 3,695.00 shares. The beta of the stock remained 0.93. MITSUI & CO., LTD. is a Japan-based diversified trading company. The Company is engaged in the sale, import, export and international trading of various products in the fields of iron and steel products, metal resource, machine and project, chemical, energy, food and retail, as well as consumer service and information industries. The Company is also engaged in the provision of retail, information communication, technology, transportation and finance services, the development of energy and raw iron resources,
Will MITSY Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)